311 related articles for article (PubMed ID: 9080938)
1. Cell-mediated and antibody responses to Bordetella pertussis antigens in children vaccinated with acellular or whole-cell pertussis vaccines. The Progetto Pertosse-CMI Working Group.
Cassone A; Ausiello CM; Urbani F; Lande R; Giuliano M; La Sala A; Piscitelli A; Salmaso S
Arch Pediatr Adolesc Med; 1997 Mar; 151(3):283-9. PubMed ID: 9080938
[TBL] [Abstract][Full Text] [Related]
2. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience.
Salmaso S; Mastrantonio P; Tozzi AE; Stefanelli P; Anemona A; Ciofi degli Atti ML; Giammanco A;
Pediatrics; 2001 Nov; 108(5):E81. PubMed ID: 11694665
[TBL] [Abstract][Full Text] [Related]
3. Acellular vaccines induce cell-mediated immunity to Bordetella pertussis antigens in infants undergoing primary vaccination against pertussis.
Ausiello CM; Urbani F; La Sala A; Lande R; Piscitelli A; Cassone A
Dev Biol Stand; 1997; 89():315-20. PubMed ID: 9272365
[TBL] [Abstract][Full Text] [Related]
4. Effect of priming with diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine or with acellular pertussis vaccine on the safety and immunogenicity of a booster dose of an acellular pertussis vaccine containing a genetically inactivated pertussis toxin in fifteen- to twenty-one-month-old children. Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine.
Podda A; Bona G; Canciani G; Pistilli AM; Contu B; Furlan R; Meloni T; Stramare D; Titone L; Rappuoli R
J Pediatr; 1995 Aug; 127(2):238-43. PubMed ID: 7636648
[TBL] [Abstract][Full Text] [Related]
5. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group.
Greco D; Salmaso S; Mastrantonio P; Giuliano M; Tozzi AE; Anemona A; Ciofi degli Atti ML; Giammanco A; Panei P; Blackwelder WC; Klein DL; Wassilak SG
N Engl J Med; 1996 Feb; 334(6):341-8. PubMed ID: 8538704
[TBL] [Abstract][Full Text] [Related]
6. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children.
Pichichero ME; Deloria MA; Rennels MB; Anderson EL; Edwards KM; Decker MD; Englund JA; Steinhoff MC; Deforest A; Meade BD
Pediatrics; 1997 Nov; 100(5):772-88. PubMed ID: 9346976
[TBL] [Abstract][Full Text] [Related]
7. Diphtheria-tetanus-acellular pertussis vaccine adsorbed (Triacelluvax; DTaP3-CB): a review of its use in the prevention of Bordetella pertussis infection.
Matheson AJ; Goa KL
Paediatr Drugs; 2000; 2(2):139-59. PubMed ID: 10937466
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children.
Pichichero ME; Edwards KM; Anderson EL; Rennels MB; Englund JA; Yerg DE; Blackwelder WC; Jansen DL; Meade BD
Pediatrics; 2000 Jan; 105(1):e11. PubMed ID: 10617748
[TBL] [Abstract][Full Text] [Related]
9. Comparison of a three-component acellular pertussis vaccine with a whole-cell pertussis vaccine in 4- through 6-year-old children. Elmwood Pediatric Associates, Pennridge Pediatric Associates.
Annunziato PW; Rothstein EP; Bernstein HH; Blatter MM; Reisinger KS; Pichichero ME
Arch Pediatr Adolesc Med; 1994 May; 148(5):503-7. PubMed ID: 8180641
[TBL] [Abstract][Full Text] [Related]
10. A cellular pertussis vaccine (Infanrix-DTPa; SB-3). A review of its immunogenicity, protective efficacy and tolerability in the prevention of Bordetella pertussis infection.
Patel SS; Wagstaff AJ
Drugs; 1996 Aug; 52(2):254-75. PubMed ID: 8841742
[TBL] [Abstract][Full Text] [Related]
11. Cell-mediated immunity and antibody responses to Bordetella pertussis antigens in children with a history of pertussis infection and in recipients of an acellular pertussis vaccine.
Ausiello CM; Lande R; Urbani F; Di Carlo B; Stefanelli P; Salmaso S; Mastrantonio P; Cassone A
J Infect Dis; 2000 Jun; 181(6):1989-95. PubMed ID: 10837180
[TBL] [Abstract][Full Text] [Related]
12. Reactogenicity and immunogenicity at preschool age of a booster dose of two three-component diphtheria-tetanus-acellular pertussis vaccines in children primed in infancy with acellular vaccines.
Tozzi AE; Anemona A; Stefanelli P; Salmaso S; Ciofi degli Atti ML; Mastrantonio P; Giammanco A;
Pediatrics; 2001 Feb; 107(2):E25. PubMed ID: 11158499
[TBL] [Abstract][Full Text] [Related]
13. Comparison of 13 acellular pertussis vaccines: overview and serologic response.
Edwards KM; Meade BD; Decker MD; Reed GF; Rennels MB; Steinhoff MC; Anderson EL; Englund JA; Pichichero ME; Deloria MA
Pediatrics; 1995 Sep; 96(3 Pt 2):548-57. PubMed ID: 7659475
[TBL] [Abstract][Full Text] [Related]
14. Antibody response and reactions to completion of a four-dose series with a two- or three-component acellular pertussis vaccine compared to whole cell pertussis vaccine.
Pichichero ME; Green JL; Francis AB; Marsocci SM; Murphy AM; Buscarino C
Scand J Infect Dis; 1996; 28(2):159-63. PubMed ID: 8792483
[TBL] [Abstract][Full Text] [Related]
15. Cell-mediated immune responses in four-year-old children after primary immunization with acellular pertussis vaccines.
Ausiello CM; Lande R; Urbani F; la Sala A; Stefanelli P; Salmaso S; Mastrantonio P; Cassone A
Infect Immun; 1999 Aug; 67(8):4064-71. PubMed ID: 10417175
[TBL] [Abstract][Full Text] [Related]
16. Vaccine- and antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines.
Ausiello CM; Urbani F; la Sala A; Lande R; Cassone A
Infect Immun; 1997 Jun; 65(6):2168-74. PubMed ID: 9169747
[TBL] [Abstract][Full Text] [Related]
17. Comparison of a three-component acellular pertussis vaccine with a whole-cell pertussis vaccine in 15- through 20-month-old infants.
Bernstein HH; Rothstein EP; Reisinger KS; Blatter MM; Arbeter AM; Fontana ME; Jacobs JM; Long SS; Rathfon H; Crayne O
Pediatrics; 1994 Apr; 93(4):656-9. PubMed ID: 8134224
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous administration of a diphtheria and tetanus toxoids and acellular pertussis vaccine with measles-mumps-rubella and oral poliovirus vaccines.
Rothstein EP; Bernstein HH; Glode MP; Laussucq S; Nonenmacher J; Long SS; Hackell JG
Am J Dis Child; 1993 Aug; 147(8):854-7. PubMed ID: 8394646
[TBL] [Abstract][Full Text] [Related]
19. Cellular immunity as a potential cause of local reactions to booster vaccination with diphtheria and tetanus toxoids and acellular pertussis antigens.
Scheifele DW; Ochnio JJ; Halperin SA
Pediatr Infect Dis J; 2009 Nov; 28(11):985-9. PubMed ID: 19755930
[TBL] [Abstract][Full Text] [Related]
20. Comparison of a fifth dose of a five-component acellular or a whole cell pertussis vaccine in children four to six years of age.
Halperin SA; Scheifele D; Barreto L; Pim C; Guasparini R; Medd L; Meekison W; Eastwood BJ
Pediatr Infect Dis J; 1999 Sep; 18(9):772-9. PubMed ID: 10493336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
